Onkologie. 2010:4(2):110-114

Anthracyclins in breast cancer therapy: pros and cons

Tomáš Svoboda
KOC FN Plzeň

Anthracyclins ranked among the basic drugs used in the adjuvant, neoadjuvant as far as in paliative treatment of breast cancer for a long

time. Their indication was based on a high eficacy. However, lot of circumstances appeared within the last years which totally change

our view on the anthracyclins position. First of all there is a fear of significant cardiotoxicity, the incidence of secondary malignancies –

leucemias and ineffectivnes in patients with HER2 and TOPO2 negative tumors. Pros and cons of the anthracycline use in breast cancer

are summarised in the following article.

Keywords: anthracyclin, paclitaxel, docetaxel, HER2 receptor, topoisomerase-2alpha

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svoboda T. Anthracyclins in breast cancer therapy: pros and cons. Onkologie. 2010;4(2):110-114.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Leonard RCF, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet). The Breast 2009; 18: 218-224. Go to original source... Go to PubMed...
    2. Jones, et al. Breast Cancer Res Treat. 2007; 106(S1): S5 [Abstract 12].
    3. Slamon, et al. Breast Cancer Res Treat. 2007; 106(S1): S5 [Abstract 13].
    4. Steinherz LJ, et al. JAMA. 1991; 266: 1672-1677.
    5. Esteva FV, Hortobagyi GN. Topoisomerase II alpha Amplification and Anthracycline-Based Chemotherapy- The Jury is Still Out. JCO, 2009; 27(21): 20. Go to original source... Go to PubMed...
    6. Pritchard KI. Are HER2 And TOP2A Usefull As Prognostic Or Predictive Biomarkers For Anthracycline-Based Adjuvant Chemotherapy For Breast Cancer? JCO 2009. Go to original source...
    7. Von Hoff DD. Semin Oncol. 1998; 25: 31-36, Swain S, et al. J Clin Oncol. 1997; 15: 1333-1340, Hensley ML, et al. J Clin Oncol. 1999; 17: 3333-3355.
    8. Pinder, et al. J Clin Oncol 2007, 25: 3308-3315.
    9. Tan-Chiu E, et al. J Clin Oncol. 2005; 23: 7811-7819.
    10. Tut, et al. Proc. ASCO 2009, Abstr. nr. CRA 501.
    11. Valero V, et al. J Clin Oncol. 1999; 17: 1425-1434, Harris L, et al. Cancer. 2002; 94: 25-36, Batist G, et al. J Clin Oncol. 2001; 19: 1444-1454.
    12. Slamon, et al. N Engl J Med 2001; 344: 783-792, Marty, et al. JCO 23: 19, July 1st 2005. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.